IMR-1A-Mediated Notch Inhibition Does Not Enhance Osteogenic Differentiation in MC3T3-E1 Cells
Faculty Mentor
Jason Ashley
Presentation Type
Poster
Start Date
4-14-2026 2:00 PM
End Date
4-14-2026 4:00 PM
Location
PUB NCR
Primary Discipline of Presentation
Biology
Abstract
Osteoporosis is characterized by reduced bone density and increased fracture risk due to impaired osteoblast differentiation. Identifying strategies to promote osteoblast differentiation could be used as a conventional line of treatment to restore bone formation. Notch is a transmembrane receptor protein that mediates a juxtacrine signaling pathway that promotes pre-osteoblast proliferation while suppressing osteoblast maturation. However, the effects of pharmacological modulation of Notch signaling in pre-osteoblasts remain incompletely understood. To test this, we examined whether inhibiting Notch signaling with IMR-1A alters osteogenic behavior in the MC3T3-E1 cell line. MC3T3-E1 cells are a well-established murine pre-osteoblast line widely used to study osteogenic differentiation and signaling pathways regulating osteogenesis in vitro. MC3T3-E1 cells were treated with increasing doses of IMR-1A and compared with a DMSO vehicle control. We assessed cell viability, proliferation, expression of the Notch target gene Hes1, and surface morphology following IMR-1A treatment. IMR-1A treatment did not significantly change cell viability, proliferation, Hes1 expression, or cellular morphology compared to the DMSO control. These findings suggest that IMR-1A treatment does not significantly change MC3T3-E1 cell function under the conditions tested. Additional optimization of pathway modulation or complementary in vivo approaches may be required to determine whether Notch inhibition can effectively influence osteoblast differentiation. Further, increasing IMR-1A concentrations may show a stronger effect on Notch signaling.
Recommended Citation
Bauer, Ethan; Nunez, Isaac; and Simpson, Justin, "IMR-1A-Mediated Notch Inhibition Does Not Enhance Osteogenic Differentiation in MC3T3-E1 Cells" (2026). 2026 Symposium. 26.
https://dc.ewu.edu/srcw_2026/ps_2026/p3_2026/26
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.
IMR-1A-Mediated Notch Inhibition Does Not Enhance Osteogenic Differentiation in MC3T3-E1 Cells
PUB NCR
Osteoporosis is characterized by reduced bone density and increased fracture risk due to impaired osteoblast differentiation. Identifying strategies to promote osteoblast differentiation could be used as a conventional line of treatment to restore bone formation. Notch is a transmembrane receptor protein that mediates a juxtacrine signaling pathway that promotes pre-osteoblast proliferation while suppressing osteoblast maturation. However, the effects of pharmacological modulation of Notch signaling in pre-osteoblasts remain incompletely understood. To test this, we examined whether inhibiting Notch signaling with IMR-1A alters osteogenic behavior in the MC3T3-E1 cell line. MC3T3-E1 cells are a well-established murine pre-osteoblast line widely used to study osteogenic differentiation and signaling pathways regulating osteogenesis in vitro. MC3T3-E1 cells were treated with increasing doses of IMR-1A and compared with a DMSO vehicle control. We assessed cell viability, proliferation, expression of the Notch target gene Hes1, and surface morphology following IMR-1A treatment. IMR-1A treatment did not significantly change cell viability, proliferation, Hes1 expression, or cellular morphology compared to the DMSO control. These findings suggest that IMR-1A treatment does not significantly change MC3T3-E1 cell function under the conditions tested. Additional optimization of pathway modulation or complementary in vivo approaches may be required to determine whether Notch inhibition can effectively influence osteoblast differentiation. Further, increasing IMR-1A concentrations may show a stronger effect on Notch signaling.
